Hence, an inhibitor of glucose uptake, like a compound “TH-G313B”, having negligible cytotoxicity, which was effective in inhibiting GLUT-mediated transfer and constrained cancer cell growth both in vitro and in vivo, would be an ideal candidate for a novel cancer treatment [223]. This evidence concerns the gene SLC2A1 and cancer.